Abstracts tagged "rheumatic disease and rheumatoid arthritis (RA)"

Abstract Number: 1240 • 2018 ACR/ARHP Annual Meeting
Foot Osteomyelitis in Inflammatory Rheumatic Diseases: A Retrospective Observational Study
Alexis HOMS¹, Patrick ABOUKRAT², Christian JORGENSEN^3,4 and Yves-Marie PERS^5,6, ¹Department of rheumatology, Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital, Montpellier, France, ²Department of physical medical rehabilitation, Lapeyronie University Hospital, Montpellier, France., Montpellier, France, ³Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, CHU Lapeyronie., Montpellier, France, ⁴biotherapy, Inserm u1183, Unite ImmunoRhumatologie Therapeutique, Montpellier, France, ⁵Clinical Immunology and Osteoarticular Diseases Therapeutic Unit, Lapeyronie University Hospital Montpellier, MONTPELLIER, France, ⁶INSERM U1183, IRMB, INSERM U1183, Montpellier, France
Background/Purpose: Foot involvement is frequently pointed by patients with chronic inflammatory rheumatic diseases (IRD), such as rheumatoid arthritis (RA), spondyloarthritis (SpA) or psoriatic arthritis (PsA).…
Abstract Number: 2915 • 2018 ACR/ARHP Annual Meeting
Can Passively-Collected Phone Behavior Determine Rheumatic Disease Activity?
Kaleb Michaud, Sofia Pedro and Rebecca Schumacher, FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS
Background/Purpose: Advances in reality mining combined with the pervasive use of smart phones have shown measurable changes in phone behavior due to changes in health.…
Abstract Number: 1586 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Alvin F. Wells¹, Maria Greenwald², John D. Bradley³, Jahangir Alam³, Vipin K. Arora³ and Cynthia E. Kartman³, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²Desert Medical Advances, Palm Desert, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral selective JAK1 and JAK2 inhibitor, has been shown to be safe and efficacious compared to placebo (PBO) in two Phase…
Abstract Number: 1590 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Roy Fleischmann¹, Jahangir Alam², Vipin Arora², John D. Bradley², Douglas E. Schlichting² and David Muram², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA. Drug-related problems are common in…
Abstract Number: 1591 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Edward Keystone², Robert Ortmann³, Maher Issa³, Li Xie³, David Muram³, John D. Bradley³, Stephanie de Bono³, Terence Rooney³ and Yoshiya Tanaka⁴, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor under investigation for the treatment of patients (pts) with moderate to severe RA.1-2 In the 52-week Phase…
Abstract Number: 1599 • 2016 ACR/ARHP Annual Meeting
Speed of Onset of Effect on Patient-Reported Outcomes Assessed through Daily Electronic Patient Diaries in the Baricitinib Phase 3 RA Clinical Program
Peter C. Taylor¹, Grace C. Wright², Carol L. Gaich³, Amy M. DeLozier³, Stephanie de Bono³, Douglas E. Schlichting³, Terence Rooney³, Jiajun Liu³, Scott D. Beattie⁴ and Maxime Dougados⁵, ¹NDORMS, University of Oxford, Oxford, United Kingdom, ²NYU Langone Medical Center, New York, NM, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Dept of Rheumatology, Cochin Hospital, Paris, France
Background/Purpose: Baricitinib (bari), an oral Janus kinase (JAK) 1/JAK2 selective inhibitor, has demonstrated clinical efficacy with a satisfactory safety profile when administered once daily in…
Abstract Number: 2584 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anemia Among Rheumatoid Arthritis Patients Treated with Conventional Disease-Modifying Antirheumatic Drugs
Jonathan Kay¹, Joshua Rancourt², John D. Bradley², Vipin K. Arora², Jinglin Zhong³, Christina Dickson² and David Muram², ¹Rheumatology Center, Memorial Campus, UMass Memorial Medical Center, Worcester, MA, ²Eli Lilly and Company, Indianapolis, IN, ³Quintiles, Rockville, MD
Background/Purpose: Anemia in rheumatoid arthritis (RA) patients (pts) has a prevalence of 16%-64% depending on population and severity of disease1,2,3 and is more common…
Abstract Number: 3027 • 2016 ACR/ARHP Annual Meeting
Herpes Zoster in Patients with Moderate to Severe Rheumatoid Arthritis Treated with Baricitinib
Kevin L. Winthrop¹, Stephen Lindsey², Michael Weinblatt³, Tsutomu Takeuchi⁴, David Hyslop⁵, Maher Issa⁵, Lei Chen⁵, John Bradley⁵, Christina Dickson⁵ and Roy Fleischmann⁶, ¹Oregon Health and Sciences University, Portland, OR, ²Ochsner Medical Center, Baton Rouge, LA, ³Division of Rheumatology, Immunology and Allergy, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Compared to the general population, RA patients (pts) have an increased risk of herpes zoster (HZ) due to their disease and various DMARD therapies…
Abstract Number: 1584 • 2016 ACR/ARHP Annual Meeting
Bari-00074565
C. Steven Ernest II, Lisa O’Brien, David Radtke, Michael Heathman, Terence Rooney, William Macias and Xin Zhang, Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective inhibitor of Janus kinases 1/2 and has demonstrated dose-dependent efficacy in moderate-to-severe RA patients who were DMARD-naïve or with…
Abstract Number: 1585 • 2016 ACR/ARHP Annual Meeting
Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib
Arthur F. Kavanaugh¹, Ronald F. van Vollenhoven², David Muram³, Jahangir Alam³, Vipin Arora³, Ana Luisa de Macedo Pinto Correia³, Inmaculada de la Torre^3,4 and James R. O'Dell⁵, ¹UC San Diego School of Medicine, La Jolla, CA, ²Rheumatology Unit, Karolinska University Hospital, Solna, Sweden, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Baricitinib (BARI), an oral JAK1/JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA.1,2 The purpose of this post hoc analysis…
Abstract Number: 1250 • 2015 ACR/ARHP Annual Meeting
DNA Methylation and Its Relation to Immunological Phenotypes in Peripheral Blood: A Study of Anti-CCP Antibody Positivity from a Population-Based Pool
Sasha Bernatsky¹, Xiaojian Shao², Marie-Michelle Simon², Marvin J. Fritzler³, Philip Awadalla^4,5, Marie Hudson⁶, Ines Colmegna⁷, Tony Kwan² and Tomi Pastinen², ¹Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ²Department of Human Genetics, McGill University and Génome Québec Innovation Centre, Montreal, QC, Canada, ³Medicine, University of Calgary, Calgary, AB, Canada, ⁴Medicine, Université de Montreal, Montreal, QC, Canada, ⁵Ontario Institute for Cancer Research, Toronto, ON, Canada, ⁶McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁷Rheumatology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: DNA methylation represents an important potential mediator of environmental influences on autoimmunity, including rheumatoid arthritis (RA). Genome-wide methylation in the context of clinical phenotypes…
Abstract Number: 1463 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibody Subclass Phenotypes in Polyarticular Juvenile Idiopathic Arthritis
Hannah Peckham¹, Lauren Bourke^2,3, Anna Radziszewska⁴, Maria Leandro⁵, Debajit Sen², Geraldine Cambridge⁶ and Yiannis Ioannou^7,8, ¹Adolescent Centre for Rheumatology Research, University College London, London, United Kingdom, ²Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ³Centre for Rheumatology Research, University College London, London, United Kingdom, ⁴The Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁵Centre for Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁷Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, ⁸Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose: Raised levels of Rheumatoid Factor (RhF) and antibodies to citrullinated proteins (ACPA), detected in the clinic using combinations of cyclic citrullinated peptides (CCP), are…
Abstract Number: 1881 • 2014 ACR/ARHP Annual Meeting
Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia
Robert S. Katz¹ and Jessica L. Polyak², ¹Rush Medical College, Chicago, IL, ²Rheumatology Associates, Chicago, IL
Background/Purpose: One area not assessed by studies to evaluate the efficacy of new medications in patients with inflammatory arthritis is whether the patient may have…
Abstract Number: 2245 • 2013 ACR/ARHP Annual Meeting
Predictive Validity Of Low Disease Activity Using Patient Reported Measures On Long-Term Outcomes In Early Rheumatoid Arthritis- Results From Study Of New Onset Rheumatoid Arthritis and Ontario Best Practices Initiative
Pooneh Akhavan¹, Binu Jacob², Paul R. Fortin³, George A. Tomlinson⁴ and Claire Bombardier^5,6, ¹Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto General Research Institute, Toronto, ON, Canada, ³University of Laval, Quebec, QC, Canada, ⁴Dept of Medicine/Rheumatology, Toronto General Hospital, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶Division of rheumatology and Department of Health Policy, Management, and Evaluation, University Health Network, Toronto, ON, Canada
Background/Purpose: Patient reported outcome measures (PROM) are used in routine practice for assessment of disease activity. They have been shown to correlate well with other…
Abstract Number: 461 • 2013 ACR/ARHP Annual Meeting
Higher TNFi Dosing Is Not Associated With More Serious Infectious Events (SIE), Elevated AST/ALT Or WBC<1.5 In The US Corrona Database
Daniel Furst¹, Mei Liu², Jeffrey D. Greenberg³ and Joel M. Kremer⁴, ¹Rheumatology, David Geffen School of Medicine, UCLA, Los Angeles, CA, ²CORRONA, Inc, Southborough, MA, ³NYU Hospital for Joint Diseases, New York, NY, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY
Higher TNFi Dosing Is Not Associated with More Serious Infectious Events (SIE), elevated AST/ALT or WBC 50 mg golim. q4wk for at least 3 months.Adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].